March 16, 2012 -- Clostridium difficile associated diarrhea (CDAD) is the leading cause of nosocomial diarrhea. The spread of this bacterium is difficult to control due to its resistant spores that survive on many surfaces.
Thus rapid detection is crucial to its control. Most rapid tests target the toxins (A & B) produced during the infection. Another diagnostic target is glutamate dehydrogenase (GDH), an enzyme produced and released during bacterial growth.
Studies have shown that adding GDH detection together with toxin detection by EIA or PCR significantly improves assay specificity.
ViroStat announces the release of three new monoclonal antibodies to Clostridia GDH validated by ELISA. These antibodies represent a new set of tools for rapid detection development.
To download the data sheet for these NEW Antibodies and to obtain pricing, go to the ViroStat website at www.virostat-inc.com or call 207-856-6620
ViroStat, Inc. is a primary manufacturer of infectious disease antigens and antibodies, supplying researchers and manufacturers since 1985. Specialties include high affinity antibodies to Flu A, Flu B, RSV & Strep A for use in rapid lateral flow devices as well as antibodies to food-borne pathogens and toxins. Also, many specificities to HCV, HBV, CMV & EBV for use in anti-viral HTS assays
PO Box 8522
Portland, ME 04104 USA